Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

PLoS One · 2015 · PMC4591284 · PMID 26426340

Europe PMC DOI

hedged sentence

0.5600

closest p · 11.2× alpha

0.5600

boldest claim

The sentences

did not reach statistical significancep = 0.56not close (p > 0.1)

The mOS of NRAS mutated patients (n = 24) was 12.1 months and although it was longer in absolute numbers compared to the mOS of BRAF mutated patients (n = 38, mOS = 8.03 months) or BRAFV600/NRASwt patients (n = 39, mOS = 8.26months) the difference did not reach statistical significance (p = 0.56).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.